Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28382564 | 0.78 | RAPGEF4 (0.33) | — | |
| SCHEMBL6193465 | 0.76 | SELL (0.33) | TSHR | |
| SCHEMBL665856 | 0.74 | DGAT1 (0.30) | — | |
| SCHEMBL17391148 | 0.74 | ALDH1A1 (0.35) | TSHR | |
| SCHEMBL8973947 | 0.70 | TSHR (0.50) | TSHRIDO1NOS3NOS1NOS2 | |
| SCHEMBL10144167 | 0.69 | TSHR (0.41) | TSHRIDO1 | |
| SCHEMBL29953333 | 0.69 | ENPP2 (0.32) | — | |
| SCHEMBL8725010 | 0.69 | HTR2A (0.36) | — | |
| SCHEMBL16494835 | 0.69 | TTR (0.37) | — | |
| SCHEMBL24602620 | 0.67 | TSHR (0.47) | TSHRIDO1NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316028-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-06-11 | — | — | US | disclosed |
| US-20180370961-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-12-27 | — | — | US | disclosed |
| US-9850237-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-12-26 | — | — | US | disclosed |
| US-20170121320-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-05-04 | — | — | US | disclosed |
| EP-2870144-B1 | OREXIN RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2017-04-19 | — | — | EP | disclosed |
| US-9555044-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-01-31 | — | — | US | disclosed |
| US-20160213678-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2016-07-28 | — | — | US | disclosed |
| EP-2060566-B1 | Poly-substituted aryls | DOW AGROSCIENCES LLC (US) | 2016-06-08 | — | — | EP | disclosed |
| US-9249160-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| EP-2870144-A1 | OREXIN RECEPTOR ANTAGONISTS | Heptares Therapeutics Limited (GB) | 2015-05-13 | — | — | EP | disclosed |
| EP-2060566-A1 | Poly-substituted aryls | Dow AgroSciences LLC (US) | 2009-05-20 | — | — | EP | disclosed |
| US-7498468-B2 | 6-(poly-substituted aryl)-4-aminopicolinates and their use as herbicides | DOW AGROSCIENCES LLC (US) | 2009-03-03 | — | — | US | disclosed |
| EP-1973881-A2 | 6-(POLY-SUBSTITUTED ARYL)-4-AMINOPICOLINATES AND THEIR USE AS HERBICIDES | Dow Agrosciences LLC (US) | 2008-10-01 | — | — | EP | disclosed |
| US-20080051596-A1 | 6-(poly-substituted aryl)-4-aminopicolinates and their use as herbicides | DOW AGROSCIENCES LLC (US) | 2008-02-28 | — | — | US | disclosed |
| US-20080045734-A1 | 6-(poly-substituted aryl)-4-aminopicolinates and their use as herbicides | DOW AGROSCIENCES LLC (US) | 2008-02-21 | — | — | US | disclosed |
| US-7314849-B2 | 6-(poly-substituted aryl)-4-aminopicolinates and their use as herbicides | DOW AGROSCIENCES LLC (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070179060-A1 | 6-(Poly-substituted aryl)-4-aminopicolinates and their use as herbicides | CORTEVA AGRISCIENCE LLC | 2007-08-02 | — | — | US | disclosed |
| WO-2007082098-A2 | 6-(POLY-SUBSTITUTED ARYL)-4-AMINOPICOLINATES AND THEIR USE AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2007-07-19 | — | — | WO | disclosed |
| US-5730901-A | Silacyclohexane compounds, preparation thereof liquid crystal compositions comprising the same, and liquid crystal devices comprising the composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1998-03-24 | — | — | US | disclosed |
| EP-0742222-A2 | Novel silacyclohexane compounds, preparation thereof, liquid crystal compositions comprising the same, and liquid crystal devices comprising the composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1996-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121320-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | TSHR 175/4885IDO1 437/4885TDO2 583/4885 |
| US-10316028-B2 | Orexin receptor antagonists | HCRTR2, HCRTR1, NPY4R | TSHR 175/4885IDO1 437/4885TDO2 583/4885 |
| US-20080045734-A1 | 6-(poly-substituted aryl)-4-aminopicolinates and their use as herbicides | AAAS, DDT, AADAC | TSHR 2822/4885IDO1 199/4885TDO2 266/4885 |
| US-20180370961-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | TSHR 175/4885IDO1 437/4885TDO2 583/4885 |
| US-20070179060-A1 | 6-(Poly-substituted aryl)-4-aminopicolinates and their use as herbicides | AAAS, DDT, AADAC | TSHR 2822/4885IDO1 199/4885TDO2 266/4885 |
| US-20080051596-A1 | 6-(poly-substituted aryl)-4-aminopicolinates and their use as herbicides | AAAS, DDT, AADAC | TSHR 2822/4885IDO1 199/4885TDO2 266/4885 |
| US-20160213678-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | TSHR 175/4885IDO1 437/4885TDO2 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.